---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037592"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:12:48.452316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023

## Summary
- Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.
- R&D expenses $59.1M, up from $46.7M; G&A $7.6M vs $6.1M.
- Cash and securities $207.7M as of June 30, 2023; funds operations through 2024.
- Enrollment ongoing in ACHIEVE (DYNE-101, DM1) and DELIVER (DYNE-251, DMD) registrational trials; initial data expected H2 2023.
- EMA granted orphan drug designation for DYNE-101 in DM1; FORCE platform CNS delivery data at ASGCT.

## SEC filing metadata
- accession: 0000950170-23-037592
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/0000950170-23-037592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/dyn-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037592
- JSON: https://secwatch.observer/filing/0000950170-23-037592.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037592.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $64.9 million, EPS $1.08 per basic and diluted share.
  - Period: the quarter ended June 30, 2023
  - Net income: $64.9 million
  - EPS: $1.08 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended June 30, 2023 was $64.9 million, or $1.08 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/0000950170-23-037592-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.